locametz Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Locametz, and what generic alternatives are available?
Locametz is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has forty-nine patent family members in sixteen countries.
The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Locametz
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for locametz?
- What are the global sales for locametz?
- What is Average Wholesale Price for locametz?
Summary for locametz
| International Patents: | 49 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for locametz |
| What excipients (inactive ingredients) are in locametz? | locametz excipients list |
| DailyMed Link: | locametz at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for locametz
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for locametz
locametz is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of locametz is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting locametz
PSMA binding ligand-linker conjugates and methods for using
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
FDA Regulatory Exclusivity protecting locametz
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for locametz
When does loss-of-exclusivity occur for locametz?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08289108
Patent: PSMA binding ligand-linker conjugates and methods for using
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 96627
Patent: CONJUGUES LIGAND-LIEUR DE LIAISON AU PSMA ET PROCEDES POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2014956
Patent: PSMA binding ligand-linker conjugates and methods for using
Estimated Expiration: ⤷ Sign Up
Patent: 4873982
Patent: PSMA binding ligand-linker conjugates and methods for using
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 87965
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 87965
Patent: CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA ET PROCÉDÉS POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 88086
Patent: CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 56403
Patent: PROCÉDÉS DE PRÉPARATION DE CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA (PREPARATION PROCESS OF PSMA BINDING LIGAND-LINKER CONJUGATES)
Estimated Expiration: ⤷ Sign Up
Patent: 31380
Patent: CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 38298
Patent: CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 58347
Patent: CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA ET PROCÉDÉS POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 12588
Patent: 結合配體-接頭綴合物及其使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PSMA -)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 47200
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3998
Patent: תצמידים קשורי ליגנד הנקשרים ל psma ושיטות לשימוש בהם (Psma binding ligand-linker conjugates and methods for using them)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 02237
Estimated Expiration: ⤷ Sign Up
Patent: 96479
Estimated Expiration: ⤷ Sign Up
Patent: 25690
Estimated Expiration: ⤷ Sign Up
Patent: 38118
Estimated Expiration: ⤷ Sign Up
Patent: 79355
Estimated Expiration: ⤷ Sign Up
Patent: 10536790
Estimated Expiration: ⤷ Sign Up
Patent: 14221779
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 16153410
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 18058864
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 18150350
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 20073472
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 21075561
Patent: ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Estimated Expiration: ⤷ Sign Up
Patent: 22110118
Patent: ＰＳＭＡ結合性リガンド－リンカー結合体及び使用方法
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3931
Patent: PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
Estimated Expiration: ⤷ Sign Up
Patent: 0085
Patent: Psma binding ligand-linker conjugates and methods for using
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 87965
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 87965
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 87965
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 68224
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering locametz around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2794581 | ⤷ Sign Up | |
| Japan | 2010536790 | ⤷ Sign Up | |
| European Patent Office | 3831380 | CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) | ⤷ Sign Up |
| Japan | 2018058864 | ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) | ⤷ Sign Up |
| Japan | 2018150350 | ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
